A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy

Author： Shin Sang  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.30, Iss.4, 2012-08, pp. : 1501-1510

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer

By Strickler John   McCall Shannon   Nixon Andrew   Brady John   Pang Herbert   Rushing Christel   Cohn Allen   Starodub Alexander   Arrowood Christy   Haley Sherri   Meadows Kellen   Morse Michael   Uronis Hope   Blobe Gerard   Hsu S.   Zafar S.   Hurwitz Herbert  

Investigational New Drugs, Vol. 32, Iss. 2, 2014-04 ,pp. : 330-339

Springer Publishing Company

Access to resources Recommend Favorite

A phase II study of S-1 plus irinotecan and oxaliplatin in heavily-treated patients with metastatic colorectal cancer

By Kim Sun   Hong Yong   Kim Byung   Park Ji   Choi Hyo   Jeong Seung-Yong   Kim Dae   Hong Chang   Sohn Dae   Jung Kyung  

Investigational New Drugs, Vol. 27, Iss. 3, 2009-06 ,pp. : 269-274

Springer Publishing Company

Access to resources Recommend Favorite

A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy

By Shin Sang  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 672-680

Springer Publishing Company

Access to resources Recommend Favorite

Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines

By Shitara Kohei  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 787-793

Springer Publishing Company

Access to resources Recommend Favorite

A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer

By Chi Kim   Chia Stephen   Dixon Ross   Newman Michael   Wacher Vince   Sikic Branimir   Gelmon Karen  

Investigational New Drugs, Vol. 23, Iss. 4, 2005-08 ,pp. : 311-315

Springer Publishing Company

Access to resources Recommend Favorite